Chicago, ILNCT04055818Now EnrollingIRB Ready

Sickle Cell Disease Clinical Trial in Chicago, IL

Access cutting-edge sickle cell disease treatment through this phase 1 clinical trial at a research site in Chicago. Study-provided care at no cost to qualified participants.

Sponsored by EpiDestiny, Inc.

Quick Self-Assessment

See if you qualify for this Chicago location

Preparing your pre-screening questions…

Expert Care in Chicago

Access sickle cell disease specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related sickle cell disease treatment provided free

Apply for This Chicago Location

Check if you qualify for this sickle cell disease clinical trial in Chicago, IL

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Chicago

    Convenient for IL residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Chicago site if eligible
  4. 4Begin participation

About This Sickle Cell Disease Study in Chicago

A randomized control trial in 20 subjects with sickle cell disease comparing oral THU-decitabine to nicotinamide and in combination (THU, decitabine and nicotinamide).

Sponsor: EpiDestiny, Inc.

Who Can Participate

Inclusion Criteria

Age 18 years or older.
Written informed consent provided by the subject before study entry.
Confirmed sickle cell disease (SCD) as determined by hemoglobin electrophoresis or liquid chromatography.
Subject is in his/her steady state and not having any acute complication due to SCD (i.e., hospitalization, acute pain, or acute chest syndrome in the past 14 days).
Weight at least 40kg
Regular compliance with comprehensive care and previous therapy.
Symptomatic SCD is defined as having one of following, despite at least 6 months of hydroxyurea therapy, or refuse to take hydroxyurea for personal reasons: fetal hemoglobin \<0.5 g/dL, or 3 or more pain episodes per year requiring parenteral narcotics, or 1 or more acute chest syndrome episodes, or Hemoglobin \<9 g/dL and absolute reticulocyte count \<250,000/mm3.

Exclusion Criteria

Inability to give informed consent.
Experienced severe sepsis or septic shock within the previous 12 weeks.
Last HU dose was ingested within the previous 4 weeks.
Currently pregnant or breast-feeding.
Alanine Aminotransferase (ALT) ≥ 3 times the upper limit of normal or albumin \<2.0 mg/dL or direct (conjugated) bilirubin ≥ 1.5 mg/dl.
Serum creatinine \>2.9 mg/dL and calculated creatinine clearance \<30 mL/min.
Platelet count \>800 x 109/L.
Absolute neutrophil count \<1.5 x 109/L.
Female of active childbearing potential who is unwilling to use at least one of the two following forms of birth control: (i) not having heterosexual sexual contact beginning at the screening visit and continuing until 4 weeks after the last dose of decitabine OR (ii) intrauterine device (IUD).
Sexually active male who is unwilling to use a condom when engaging in any sexual contact with a female with child-bearing potential, beginning at the screening visit and continuing until 4 weeks after taking the last dose of THU and decitabine. This requirement applies also to males who have had a successful vasectomy.
Altered mental status or recurrent seizures requiring anti-seizure medications.
Moribund or any concurrent disease (e.g., hepatic, renal, cardiac, metabolic) of such severity that death within 24 weeks is likely.
Concurrent diagnosis of malignancy including known Myelodysplastic syndrome, leukemia, or an abnormal karyotype.
New York Heart Association (NYHA) class III/IV status.
Eastern Co-operative Oncology Group (ECOG) performance status ≥3.
Participant is on chronic transfusion therapy
Known history of illicit drug or alcohol abuse within the past 12 months.
Other experimental or investigational drug therapy in the past 28 days.
Taking l-glutamine within the last 28 days
Being positive for HIV infection

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Chicago?

Yes, this clinical trial (NCT04055818) has an active research site in Chicago, IL that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Sickle Cell Disease Treatment Options in Chicago, IL

If you're searching for sickle cell disease treatment options in Chicago, IL, this clinical trial (NCT04055818) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Chicago research site is actively enrolling participants for this phase 1 clinical trial. You'll receive care from experienced sickle cell disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all sickle cell disease clinical trials near you to find additional studies recruiting in your area.

More Ankylosing Spondylitis Trials in Chicago, IL

See all ankylosing spondylitis clinical trials recruiting in Chicago — not just this study.

Browse Ankylosing Spondylitis Trials in Chicago →

Browse More Trials by Condition

Ankylosing Spondylitis TrialsInterstitial Cystitis TrialsSickle Cell Disease TrialsAll Conditions →

Ready to Join in Chicago?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Chicago, IL